A detailed history of Price T Rowe Associates Inc transactions in Veru Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 106,109 shares of VERU stock, worth $77,459. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106,109
Previous 63,300 67.63%
Holding current value
$77,459
Previous $45,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.76 - $1.79 $32,534 - $76,628
42,809 Added 67.63%
106,109 $90,000
Q4 2023

Feb 14, 2024

BUY
$0.67 - $1.17 $25,460 - $44,460
38,000 Added 150.2%
63,300 $46,000
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.49 $26,823 - $40,782
-27,371 Reduced 51.97%
25,300 $31,000
Q1 2023

May 15, 2023

BUY
$1.16 - $6.41 $13,699 - $75,702
11,810 Added 28.9%
52,671 $62,000
Q4 2022

Feb 14, 2023

BUY
$4.78 - $15.01 $6,352 - $19,948
1,329 Added 3.36%
40,861 $216,000
Q3 2022

Nov 14, 2022

SELL
$10.22 - $23.7 $421,595 - $977,672
-41,252 Reduced 51.06%
39,532 $456,000
Q2 2022

Aug 15, 2022

BUY
$4.35 - $15.85 $58,281 - $212,358
13,398 Added 19.88%
80,784 $913,000
Q1 2022

May 16, 2022

BUY
$4.55 - $6.41 $7,280 - $10,256
1,600 Added 2.43%
67,386 $325,000
Q4 2021

Feb 14, 2022

BUY
$5.89 - $9.73 $91,571 - $151,272
15,547 Added 30.95%
65,786 $387,000
Q3 2021

Nov 15, 2021

BUY
$6.78 - $9.89 $75,258 - $109,779
11,100 Added 28.36%
50,239 $429,000
Q2 2021

Aug 16, 2021

BUY
$7.24 - $11.2 $59,939 - $92,724
8,279 Added 26.83%
39,139 $316,000
Q1 2021

May 17, 2021

SELL
$8.05 - $20.78 $26,637 - $68,761
-3,309 Reduced 9.68%
30,860 $333,000
Q4 2020

Feb 16, 2021

BUY
$2.36 - $9.99 $80,638 - $341,348
34,169 New
34,169 $296,000

Others Institutions Holding VERU

About VERU INC.


  • Ticker VERU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,146,704
  • Market Cap $58.5M
  • Description
  • Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N....
More about VERU
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.